Page last updated: 2024-12-05

bis(p-chlorophenyl)acetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(p-chlorophenyl)acetic acid: a metabolite of DDT; RN given refers to parent cpd. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bis(4-chlorophenyl)acetic acid : A organochlorine compound comprising acetic acid having two 4-chlorophenyl substituents attached at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6730
CHEMBL ID1879491
CHEBI ID28139
SCHEMBL ID467546
MeSH IDM0040808

Synonyms (66)

Synonym
2,2-bis(4-chlorophenyl)-acetic acid
di(p-chlorophenyl)acetic acid
p,p'-dda
2,2-bis(4-chlorophenyl)acetic acid
bis(p-chlorphenyl)essigsaeure
bis(4-chlorophenyl)acetic acid
benzeneacetic acid, 4-chloro-.alpha.-(4-chlorophenyl)-
wln: qyvr dg&r dg
nsc-4279
acetic acid, bis(p-chlorophenyl)-
nsc4279
p,p'-dichlorodiphenylacetic acid
2,2-bis(p-chlorophenyl)acetic acid
bis(p-chlorophenyl)acetic acid
dichlorodiphenylacetic acid
4-chloro-alpha-(4-chlorophenyl)benzeneacetic acid
benzeneacetic acid, 4-chloro-alpha-(4-chlorophenyl)-
bis(p-chlorphenyl)essigsaeure [german]
ai3-07573
brn 1913593
einecs 201-451-8
nsc 4279
OPREA1_249828
C06640
bis(4'-chlorophenyl)acetate
83-05-6
SR-01000389220-2
bis(4-chlorophenyl)acetic acid, 98%
NCGC00164026-01
MAYBRIDGE1_006953
AKOS001584787
HMS561E01
FT-0652766
A840496
CHEBI:28139 ,
dtxsid3040699 ,
dtxcid1020699
cas-83-05-6
tox21_301432
NCGC00255690-01
CCG-45383
GEO-02561
unii-n0u8s29g6e
n0u8s29g6e ,
AB01331060-02
2,2-bis-(4-chloro-phenyl)-acetic acid
bis(4-chlorophenyl) acetic acid
bis-(4-chloro-phenyl)-acetic acid
mfcd00004248
SCHEMBL467546
W-200512
CHEMBL1879491
BBL034637
acetic acid, bis-(4-chlorophenyl)
STL415948
dda, p,p'-
4-chloro-.alpha.-(4-chlorophenyl)benzeneacetic acid
sr-01000389220
SR-01000389220-1
4,4'-dda, pestanal(r), analytical standard
AS-62049
4,4'-dda
Q27103524
NCGC00164026-02
CS-0134772
2,2-bis(4-chlorophenyl)aceticacid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves demonstrated a close relationship between the inhibitory effects of DXS on the DTH and the A-PE/DDA complex formation."( Suppression of the cellular adjuvanticity of lipophilic amines by a polyanion.
Hilgers, LA; Jansze, M; Snippe, H; van Vliet, KE; Willers, JM, 1986
)
0.27
"All DDT metabolites tested revealed a clear dose-response relationship for cytotoxicity in RTG-2 cells, but no dioxin-like activities with RTL-W1 cells."( Toxicity, dioxin-like activities, and endocrine effects of DDT metabolites--DDA, DDMU, DDMS, and DDCN.
Braunbeck, T; Erdinger, L; Hallare, AV; Hollert, H; Otte, JC; Rastall, A; Ricking, M; Schwarzbauer, J; Wetterauer, B, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency38.74680.000214.376460.0339AID588532; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.95440.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.72680.001019.414170.9645AID588537; AID743094; AID743140; AID743191
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (58.82)18.7374
1990's7 (13.73)18.2507
2000's4 (7.84)29.6817
2010's8 (15.69)24.3611
2020's2 (3.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.62 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]